CRISPR Therapeutics AG
SEC EDGAR quarterly and annual company filings
Past bets that played out
These are the clearest thesis calls with observable outcomes, linked back to the original videos.
The provided excerpt is only the cover/table-of-contents portion of CRISPR Therapeutics’ Form 10-Q for quarter ended 2026-03-31. It confirms filing status, exchange listing (Nasdaq: CRSP), and basic corporate identifiers, but contains no financial results, guidance, pipeline updates, cash runway, risk-factor changes, or other value-moving disclosures. As-is, it is not tradable/actionable.
This excerpt is only the cover page/header of CRISPR Therapeutics’ FY2025 Form 10‑K (fiscal year ended 2025‑12‑31). It contains listing/filing status information but no financial results, guidance, risk updates, pipeline progress, or MD&A detail—so it provides minimal tradable signal by itself.
This excerpt is only the cover/boilerplate of CRISPR Therapeutics’ 10‑Q for the quarter ended 2025‑09‑30 and does not include financial results, cash runway, pipeline updates, guidance, or risk-factor changes. As provided, it offers minimal tradable, incremental information beyond confirming continued SEC reporting/listing compliance.
What this channel is watching now
Recent mentions show where this author is concentrating attention right now.
Latest videos and market context
Recent source posts from this author. Create an account to inspect the complete persisted research trail.
GEV 10-Q report for 2026-06-30
The provided excerpt is only the Form 10‑Q cover page for GE Vernova Inc. (GEV) for quarter ended 2026‑06‑30, with no financial statements, MD&A, segment results, guidance, backlog, risks, or other performance details included. As-is, it contains almost no trade-relevant incremental information beyond confirming the filing/period and listing details.
SNBR 10-Q report for 2026-04-04
This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.
SOUN 10-Q report for 2026-03-31
The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.
WEAT 10-Q report for 2026-03-31
The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).
Proof-backed call history
These are recent thesis calls tied to original source content where available.
The provided excerpt is only the cover/table-of-contents portion of CRISPR Therapeutics’ Form 10-Q for quarter ended 2026-03-31. It confirms filing status, exchange listing (Nasdaq: CRSP), and basic corporate identifiers, but contains no financial results, guidance, pipeline updates, cash runway, risk-factor changes, or other value-moving disclosures. As-is, it is not tradable/actionable.
This excerpt is only the cover page/header of CRISPR Therapeutics’ FY2025 Form 10‑K (fiscal year ended 2025‑12‑31). It contains listing/filing status information but no financial results, guidance, risk updates, pipeline progress, or MD&A detail—so it provides minimal tradable signal by itself.
This excerpt is only the cover/boilerplate of CRISPR Therapeutics’ 10‑Q for the quarter ended 2025‑09‑30 and does not include financial results, cash runway, pipeline updates, guidance, or risk-factor changes. As provided, it offers minimal tradable, incremental information beyond confirming continued SEC reporting/listing compliance.
Provided excerpt is only the cover/header portion of CRISPR Therapeutics AG’s Form 10-Q for the quarter ended 2025-06-30 (listing symbol/exchange and SEC filing compliance checkboxes). It contains no financial statements, guidance, program updates, or risk-factor changes, so it is minimally actionable for trading beyond confirming continued reporting/listing compliance.
About this channel
Channel bio, source link, and public-market context from YouTube.
SEC EDGAR quarterly and annual company filings
Most recognized assets
Unlock the full track record
Create an account to inspect the complete author history, trust-weighted rankings, and persisted research across authors, theses, and assets.